Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simiao Sanjie Decoction
- Development stage
- Preclinical
- Lead developer
- Capital's Funds for Health Improvement and Research
- Administration
- Oral
01
Overview
Simiao Sanjie Decoction is a Traditional Chinese Medicine (TCM) formulation currently being investigated for its effectiveness in the treatment of high-risk subsolid pulmonary nodules. It is administered as granules.
- Other names
- Si Miao Sanjie granules
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)ALB (Human serum albumin)EGFR (Epidermal growth factor receptor)IL-6 (Interleukin 6)JAK2 (Janus kinase 2)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Simiao Sanjie Decoction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simiao Sanjie Decoction.